SYNACT PHARMA ApS
CVR 34459975 · Private limited company (ApS) · Active · Low risk
SYNACT PHARMA ApS is a Private limited company (ApS), founded on , based in Holte. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 0.5% over the next 12 months, which is 0.4 times the average for Danish companies. 14 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 20.3m and a net result of DKK -59.8m. CEO: Thomas Boesen, Ann Kristin Brøgger Led.
Bankruptcy risk for SYNACT PHARMA ApS
0.4 × the average (1.41%) · higher risk than 59% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 34459975
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (14 years)
- Address
- Dronninggårds Alle 136
2840 Holte - Municipality
- Rudersdal
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 1.0m
- Auditor
- KPMG P/S
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 14 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 63.4% |
| Current ratio | 217% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 8 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 32 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -53.2m | DKK -26.3m |
| Net profit | DKK -59.8m | DKK -30.5m |
| Equity | DKK 20.3m | DKK 25.1m |
| Total assets | DKK 32.0m | DKK 37.8m |
| Cash | DKK 11.7m | – |
| Short-term debt | DKK 10.5m | – |
| Avg. employees | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · KPMG P/S.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 153 | ||
| 1 Jan 2024 – 31 Dec 2024 | 178 | ||
| 1 Jan 2023 – 31 Dec 2023 | 172 | ||
| 1 Jan 2022 – 31 Dec 2022 | 150 | ||
| 1 Jan 2021 – 31 Dec 2021 | 144 | ||
| 1 Jan 2020 – 31 Dec 2020 | 151 | ||
| 1 Jan 2019 – 31 Dec 2019 | 119 | ||
| 1 Jan 2018 – 31 Dec 2018 | 143 | ||
| 1 Jan 2017 – 31 Dec 2017 | 151 | ||
| 1 Jan 2016 – 31 Dec 2016 | 171 | ||
| 1 Jan 2015 – 31 Dec 2015 | 78 | ||
| 1 Jan 2014 – 31 Dec 2014 | 139 | ||
| 1 Jan 2013 – 31 Dec 2013 | 161 | ||
| 14 Mar 2012 – 31 Dec 2012 | 168 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Thomas Boesen | Current | |
| CEO | Ann Kristin Brøgger Led | Current | |
| CEO | Henrik Stage | ||
| CEO | Patrik Renblad | ||
| CEO | Björn Uno Bernhard Westberg | ||
| Board | Sigbjørn Georg Nielsen Kjærgård | ||
| Board | Jørn Frederik Falch | ||
| Board | Uli Alf Hacksell | ||
| Board | Otto Bjerg Hausgaard | ||
| Board | Thomas Engelbrecht Nordkild Jonassen | ||
| Owner (100%) | SynAct Pharma AB | Current | |
| Owner (25%) | Forsknings-, Uddannelses- og Digitaliseringsministeriet | ||
| Owner (33%) | NORDIC BIOTECH HOLDING ApS | ||
| Owner (0%) | TJ BIOTECH HOLDING ApS | ||
| Owner (5%) | NORDIC BIOTECH HOLDING ApS | ||
| Owner (33%) | TJ BIOTECH HOLDING ApS | ||
| Owner (25%) | QUANTASS ApS | ||
| Owner (5%) | Next Stage Ventures ApS | ||
| Owner (10%) | GL Capital AB | ||
| Auditor | KPMG P/S | Current | |
| Auditor | Bruno Sten Rosenkrans Jensen | ||
| Auditor | DANSK REVISION MARIAGERFJORD, STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Auditor | Forvis Mazars Statsautoriseret Revisionspartnerselskab | ||
| Founder | NORDIC BIOTECH HOLDING ApS | Current |
The CEOs' other companies
Thomas Boesen – 10 other companies
- Boesen Biotech ApS Active
- Boesen Consult ApS Opløst
- EV-EL ApS Active
- FISSION HOLDING ApS Fusioneret
- Gudter ApS Active
- MEDCHEM ApS Opløst
- MEDCHEM HOLDING ApS Opløst
- T. BOESEN HOLDING 2013 ApS Fusioneret
- T. BOESEN HOLDING ApS Active
- T. Boesen Holding 2017 ApS Fusioneret
Ann Kristin Brøgger Led – 1 other companies
- MedTrace Pharma A/S Active
Henrik Stage – 10 other companies, of which 1 bankrupt
- CARAXESS A/S Bankrupt 22 Nov 2002
- Adcendo ApS Active
- Biomia ApS Active
- Fuse Vectors ApS Active
- NSF VI Helgeshøj Allé ApS Active
- RHOVAC ApS Active
- RICC A/S Active
- ResoTher Pharma A/S Active
- Skape Bio ApS Active
- iNotify ApS Active
Address history (4 moves)
| Dronninggårds Alle 136, 2840 Holte | |
| c/o Quantass ApS, Turbinevej 1, 3150 Hellebæk | |
| c/o CAPNOVA A/S, Åbogade 15, 8200 Aarhus N | |
| Brendstrupgårdsvej 102, 8200 Aarhus N | |
| Åbogade 15, 8200 Aarhus N |
Former names
| SYNACT PHARMA ApS | – now |
| SYNACTION PHARMA ApS | – |
Other companies at the same address
- GIRI SERVICES ApS Bankrupt
- JS PrivateNurses ApS Bankrupt
- PERSONALEZONEN A/S Bankrupt
- SALES ACADEMY ApS Bankrupt
- AFTER WORK 2014 ApS Active
- ALTRAPHARMA HOLDING ApS Fusioneret
- Adelis DK 5 Holding A/S Opløst
- Aktieselskabet af 22. januar 2020 Opløst
- BioInvest ApS Fusioneret
- Brand People ApS Opløst
- CONSENSUS ALTO ApS Fusioneret
- FREJ ApS Active
- Freescale Semiconductor Danmark A/S Fusioneret
- Gina Holding A/S Opløst
- HF Capital ApS Active
- HFT HOLDING ApS Active
- Holledig Capital I Komplementar ApS Active
- Jentzen & Partners ApS Active
- Komplementarselskabet af 2. november ApS Opløst
- L & S MANAGEMENT ApS Opløst
- LOTUS PAPER ApS Opløst
- MLH HOLDCO ApS Active
- NYALA ApS Active
- NÆSSESLOTTET ApS Active
- PEVASTER A/S Opløst
Similar companies in Rudersdal
- ALK-ABELLÓ A/S Hørsholm
- AleSac ApS Holte
- Breye Therapeutics ApS Hørsholm
- Remecure ApS Holte
- Allarity Therapeutics Denmark ApS Hørsholm
- Allarity Therapeutics Europe ApS Hørsholm
- SCANPHARM A/S Birkerød
- Højbo Healthcare ApS Vedbæk
- Bacthera Denmark A/S Hørsholm
- AddMe Consulting ApS Vedbæk
- Inpare ApS Hørsholm
Questions and answers about SYNACT PHARMA ApS
Has SYNACT PHARMA ApS gone bankrupt?
No, SYNACT PHARMA ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of SYNACT PHARMA ApS?
Our model estimates a bankruptcy risk of 0.5% over the next 12 months (low risk), which is 0.4 times the average for Danish companies.
Who is the CEO of SYNACT PHARMA ApS?
Thomas Boesen, Ann Kristin Brøgger Led are the CEOs of SYNACT PHARMA ApS.
Who is the auditor of SYNACT PHARMA ApS?
SYNACT PHARMA ApS most recently used KPMG P/S.
When was SYNACT PHARMA ApS founded?
SYNACT PHARMA ApS was founded on 14 March 2012.
What is the equity of SYNACT PHARMA ApS?
Equity was DKK 20.3m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.